Cardlytics Announces Fourth Quarter and Full Year 2023 Financial Results
- Positive growth in Total Revenue, Billings, and Adjusted Contribution for Q4 and full year 2023.
- Achieved positive Adjusted EBITDA for the first time since 2019.
- Plans for double-digit billings growth in 2024 and positive operating cash flow.
- Improved cost structure and focus on building a best-in-class platform for partners and advertisers.
- Increase in Cardlytics MAUs and stable ARPU for Q4 and full year 2023.
- None.
Insights
Cardlytics' financial performance indicates a positive trajectory, evidenced by an 8.1% year-over-year increase in Q4 revenue and a 3.6% increase for the full year. The shift to positive Adjusted EBITDA after several years is a pivotal moment, reflecting improved operational efficiency and cost management. The reported net loss reduction from $(378.3) million to $(100.8) million is substantial. However, the continued net loss raises questions about the company's long-term profitability and the sustainability of its growth model. The increase in MAUs is a positive sign of market penetration, but the stagnant ARPU suggests a need for improved monetization strategies.
Cardlytics' focus on enhancing its digital advertising platform resonates with current industry trends towards targeted and personalized ad experiences. The reported growth in billings and adjusted contribution indicates that advertisers find value in Cardlytics' offerings. The company's forward guidance suggests confidence in continued growth, but it's essential to monitor if this translates into sustained positive free cash flow, which remains a critical metric for assessing the health of a business in the competitive ad tech landscape.
Investors should note the mixed signals in Cardlytics' report. On one hand, the positive Adjusted EBITDA and operational cash flow point to a potentially brighter financial future. On the other hand, the company's net losses and the slight decrease in ARPU year-over-year warrant caution. The guidance for Q1 2024, with Adjusted EBITDA ranging from a loss to breakeven, suggests that while the company is making progress, there's still uncertainty ahead. Investors should weigh these factors against the backdrop of the broader economic environment and the performance of the digital advertising sector.
ATLANTA, March 14, 2024 (GLOBE NEWSWIRE) -- Cardlytics, Inc. (NASDAQ: CDLX), a digital advertising platform, today announced financial results for the fourth quarter and full year ended December 31, 2023. Supplemental information is available on the Investor Relations section of the Cardlytics website at http://ir.cardlytics.com/.
"The fourth quarter capped a transformational year for Cardlytics," said Karim Temsamani, CEO of Cardlytics. "With our cost structure rebalanced, we can now focus on building a best-in-class platform with top-tier targeting and a differentiated user experience that will help deliver the best outcomes for our partners, their customers and our advertisers."
"Achieving growth and improving our capital structure are our top priorities," said Alexis DeSieno, CFO of Cardlytics. "In 2023, we turned to full year positive Adjusted EBITDA for the first time since 2019, and our Q1 guidance implies further acceleration. We are on a path to double-digit billings growth in 2024 and positive operating cash flow on an annual basis."
Fourth Quarter 2023 Financial Results
- Total Revenue was
$89.2 million , an increase of8.1% compared to$82.5 million in the fourth quarter of 2022. - Billings, a non-GAAP metric, was
$131.9 million , an increase of4.6% compared to$126.1 million in the fourth quarter of 2022. - Adjusted Contribution, a non-GAAP metric, was
$47.3 million , an increase of$7.3 million compared to$40.0 million in the fourth quarter of 2022. - Net Loss attributable to common stockholders was
$(100.8) million , or$(2.56) per diluted share, based on 39.5 million weighted-average common shares outstanding, compared to a Net Loss attributable to common stockholders of$(378.3) million , or$(11.32) per diluted share, based on 33.4 million weighted-average common shares outstanding in the fourth quarter of 2022. - Adjusted EBITDA, a non-GAAP metric, was
$10.0 million , an increase of$16.1 million compared to$(6.1) million in the fourth quarter of 2022. - Adjusted Net Income (Loss), a non-GAAP metric, was
$5.7 million , or$0.14 per diluted share, based on 39.5 million weighted-average common shares outstanding in the fourth quarter of 2023, compared to a Adjusted Net Loss of$(9.7) million , or$(0.29) per diluted share, based on 33.4 million weighted-average common shares outstanding in the fourth quarter of 2022. - Net cash provided by operating activities was
$2.9 million , an increase of$16.0 million compared to net cash used in operating activities of$(13.1) million in the fourth quarter of 2022. - Free Cash Flow, a non-GAAP metric, was
$(0.8) million , an increase of$15.5 million compared to$(16.3) million in the fourth quarter of 2022.
Fiscal Year 2023 Financial Results
- Total Revenue was
$309.2 million , an increase of3.6% compared to$298.5 million in 2022. - Billings, a non-GAAP metric, was
$453.4 million , an increase of2.5% compared to$442.5 million in 2022. - Adjusted Contribution, a non-GAAP metric, was
$158.6 million , an increase of10.9% compared to$143.0 million in 2022. - Net Loss attributable to common stockholders was
$(134.7) million , or$(3.69) per diluted share, based on 36.5 million weighted-average common shares outstanding, compared to a Net Loss attributable to common stockholders of$(465.3) million , or$(13.92) per diluted share, based on 33.4 million weighted-average common shares outstanding in 2022. - Adjusted EBITDA, a non-GAAP metric, was
$3.8 million , an increase of$48.9 million compared to$(45.2) million in 2022. - Adjusted Net Loss, a non-GAAP metric, was
$(11.4) million , or$(0.31) per diluted share, based on 36.5 million weighted-average common shares outstanding in 2023, compared to a Adjusted Net Loss of$(60.3) million , or$(1.80) per diluted share, based on 33.4 million weighted-average common shares outstanding in 2022. - Net cash used in operating activities was
$(0.2) million , an increase of$53.7 million compared to$(53.9) million in 2022. - Free Cash Flow, a non-GAAP metric, was
$(12.6) million an increase of$54.8 million compared to$(67.4) million in 2022.
Key Metrics
- Cardlytics MAUs in the quarter were 168.0 million, an increase of
7.1% compared to 156.9 million in the fourth quarter of 2022. For full year 2023, Cardlytics MAUs were 162.1 million, an increase of4.9% compared to 154.6 million in 2022. - Cardlytics ARPU was
$0.53 for each of the fourth quarters for 2023 and 2022. For the full year 2023 Cardlytics ARPU was$1.91 , a decrease of1.3% compared to$1.93 in 2022.
Definitions of MAUs and ARPU are included below under the caption “Non-GAAP Measures and Other Performance Metrics.”
First Quarter 2024 Financial Expectations
Cardlytics anticipates billings, revenue, adjusted contribution and adjusted EBITDA to be in the following ranges (in millions):
| Q1 2024 Guidance | |
| Billings(1) | |
| Revenue | |
| Adjusted Contribution(2) | |
| Adjusted EBITDA(3) | ( |
| (1) A reconciliation of billings to GAAP Revenue on a forward-looking basis is presented below under the heading "Reconciliation of Forecasted GAAP Revenue to Billings." (2) A reconciliation of Adjusted Contribution to GAAP Gross Profit on a forward-looking basis is not available without unreasonable efforts due to the high variability, complexity and low visibility with respect to the items excluded from this non-GAAP measure. (3) A reconciliation of Adjusted EBITDA to GAAP Net Loss on a forward-looking basis is not available without unreasonable efforts due to the high variability, complexity and low visibility with respect to the items excluded from this non-GAAP measure. | |
Earnings Teleconference Information
Cardlytics will discuss its fourth quarter and full year 2023 financial results during a teleconference today, March 14, 2024, at 5:00 PM ET / 2:00 PM PT. A live dial-in will be available after registering at http://ir.cardlytics.com/. Shortly after the conclusion of the call, a replay of this conference call will be available through 8:00 PM ET on March 22, 2024 on the Cardlytics Investor Relations website at http://ir.cardlytics.com/. Following the completion of the call, a recorded replay of the webcast will be available on Cardlytics’ website.
About Cardlytics
Cardlytics (NASDAQ: CDLX) is a digital advertising platform. We partner with financial institutions to run their rewards programs that promote customer loyalty and deepen relationships. In turn, we have a secure view into where and when consumers are spending their money. We use these insights to help marketers identify, reach, and influence likely buyers at scale, as well as measure the true sales impact of marketing campaigns. Headquartered in Atlanta, Cardlytics has offices in Menlo Park, Los Angeles, New York, and London. Learn more at www.cardlytics.com.
Cautionary Language Concerning Forward-Looking Statements:
This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, our financial guidance for the first quarter of 2024, our billings and positive operating cash flow expectations for 2024, and our platform improvements. These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," "intend," or variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control.
Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: risks related to unfavorable conditions in the global economy and the industries that we serve; our quarterly operating results have fluctuated and may continue to vary from period to period; our ability to sustain our revenue growth and billings; risks related to our substantial dependence on our Cardlytics platform; risks related to our substantial dependence on JPMorgan Chase Bank, National Association (“Chase”), Bank of America, National Association ("Bank of America"), Wells Fargo Bank, National Association (“Wells Fargo”) and a limited number of other financial institution (“FI”) partners; risks related to our ability to maintain relationships with Chase, Wells Fargo and Bank of America; the amount and timing of budgets by marketers, which are affected by budget cycles, economic conditions and other factors; our ability to generate sufficient revenue to offset contractual commitments to FI partners; our ability to attract new partners, including FI partners, and maintain relationships with bank processors and digital banking providers; our ability to maintain relationships with marketers; our ability to adapt to changing market conditions, including our ability to adapt to changes in consumer habits, negotiate fee arrangements with new and existing partners and retailers, and develop and launch new services and features; and other risks detailed in the “Risk Factors” section of our Form 10-K filed with the Securities and Exchange Commission on March 14, 2024 and in subsequent periodic reports that we file with the Securities and Exchange Commission. Past performance is not necessarily indicative of future results.
The forward-looking statements included in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Non-GAAP Measures and Other Performance Metrics
To supplement the financial measures presented in our press release and related conference call or webcast in accordance with generally accepted accounting principles in the United States (“GAAP”), we also present the following non-GAAP measures of financial performance in this press release: Billings, Adjusted Contribution, Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per share and Free Cash Flow, as well as certain other performance metrics, such as monthly active users (“MAUs”) and average revenue per user (“ARPU”).
A “non-GAAP financial measure” refers to a numerical measure of our historical or future financial performance or financial position that is included in (or excluded from) the most directly comparable measure calculated and presented in accordance with GAAP in our financial statements. We provide certain non-GAAP measures as additional information relating to our operating results as a complement to results provided in accordance with GAAP. The non-GAAP financial information presented herein should be considered in conjunction with, and not as a substitute for or superior to, the financial information presented in accordance with GAAP and should not be considered a measure of liquidity. There are significant limitations associated with the use of non-GAAP financial measures. Further, these measures may differ from the non-GAAP information, even where similarly titled, used by other companies and therefore should not be used to compare our performance to that of other companies.
Billings represents the gross amount billed to customers and marketers for services in order to generate revenue. Cardlytics platform Billings is recognized gross of both Consumer Incentives and Partner Share. Cardlytics platform GAAP Revenue is recognized net of Consumer Incentives and gross of Partner Share. Bridg platform Billings is the same as Bridg platform GAAP Revenue. We define Adjusted Contribution as a measure by which revenue generated from our marketers exceeds the cost to obtain the purchase data and the digital advertising space from our partners. Adjusted Contribution demonstrates how incremental revenue on our platforms generates incremental amounts to support our sales and marketing, research and development, delivery costs, general and administration and other investments. Adjusted Contribution is calculated by taking our total revenue less our Partner Share and other third-party costs. Adjusted contribution does not take into account all costs associated with generating revenue from advertising campaigns, including sales and marketing expenses, research and development expenses, general and administrative expenses and other expenses, which we do not take into consideration when making decisions on how to manage our advertising campaigns. We define Adjusted EBITDA represents our Net Loss before income tax benefit; interest expense, net; depreciation and amortization; stock-based compensation expense; acquisition, integration and divestiture costs (benefits); change in fair value of contingent consideration; foreign currency (gain) loss; impairment of goodwill and intangible assets; loss on divestiture; and restructuring and reduction of force. We define Adjusted Net Income (Loss) as our Net Loss before stock-based compensation expense; foreign currency (gain) loss; acquisition, integration and divestitures costs (benefits); amortization of acquired intangibles; change in fair value of contingent consideration; impairment of goodwill and intangible assets; loss on divestiture; restructuring and reduction of force; and income tax benefit. We define Adjusted Net Income (Loss) per share as Adjusted Net Income (Loss) divided by our weighted-average common shares outstanding, diluted. We define Free Cash Flow as net cash provided by (used in) operating activities, plus acquisition of property and equipment, acquisition of patents and capitalized software development costs. We believe free cash flow is useful to measure the funds generated in a given period that are available to invest in the business. We believe this supplemental information enhances stockholders' ability to evaluate our performance.
We believe the use of non-GAAP financial measures, as a supplement to GAAP measures, is useful to investors in that they eliminate items that are either not part of our core operations or do not require a cash outlay, such as stock-based compensation expense. Management uses these non-GAAP financial measures when evaluating operating performance and for internal planning and forecasting purposes. We believe that these non-GAAP financial measures help indicate underlying trends in the business, are important in comparing current results with prior period results, and are useful to investors and financial analysts in assessing operating performance.
We define MAUs as targetable customers that have logged in and visited online or mobile applications containing offers, opened an email containing an offer, or redeemed an offer from the Cardlytics platform during a monthly period. We then calculate a monthly average of these MAUs for the periods presented. We define ARPU as the total Revenue generated in the applicable period calculated in accordance with GAAP, divided by the average number of MAUs in the applicable period.
| CARDLYTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in thousands) | ||||||||
| December 31, | ||||||||
| 2023 | 2022 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 91,830 | $ | 121,905 | ||||
| Restricted cash | — | 80 | ||||||
| Accounts receivable and contract assets, net | 120,622 | 115,609 | ||||||
| Other receivables | 5,379 | 4,470 | ||||||
| Prepaid expenses and other assets | 6,097 | 7,978 | ||||||
| Total current assets | 223,928 | 250,042 | ||||||
| Long-term assets: | ||||||||
| Property and equipment, net | 3,323 | 5,916 | ||||||
| Right-of-use assets under operating leases, net | 7,310 | 6,571 | ||||||
| Intangible assets, net | 35,003 | 53,475 | ||||||
| Goodwill | 277,202 | 352,721 | ||||||
| Capitalized software development costs, net | 24,643 | 19,925 | ||||||
| Other long-term assets, net | 2,735 | 2,586 | ||||||
| Total assets | $ | 574,144 | $ | 691,236 | ||||
| Liabilities and stockholders' equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 4,425 | $ | 3,765 | ||||
| Accrued liabilities: | ||||||||
| Accrued compensation | 11,662 | 10,486 | ||||||
| Accrued expenses | 9,587 | 21,335 | ||||||
| Partner Share liability | 48,867 | 48,593 | ||||||
| Consumer Incentive liability | 52,678 | 53,983 | ||||||
| Deferred revenue | 2,405 | 1,751 | ||||||
| Current operating lease liabilities | 2,127 | 4,910 | ||||||
| Current contingent consideration | 39,398 | 104,121 | ||||||
| Total current liabilities | 171,149 | 248,944 | ||||||
| Long-term liabilities: | ||||||||
| Convertible senior notes, net | 227,504 | 226,047 | ||||||
| Long-term debt | 30,073 | — | ||||||
| Long-term deferred revenue | 67 | 334 | ||||||
| Long-term operating lease liabilities | 6,391 | 4,306 | ||||||
| Long-term contingent consideration | 4,162 | — | ||||||
| Total liabilities | 439,346 | 479,631 | ||||||
| Stockholders’ equity: | ||||||||
| Common stock | 9 | 9 | ||||||
| Additional paid-in capital | 1,243,594 | 1,182,568 | ||||||
| Accumulated other comprehensive income | 2,467 | 5,598 | ||||||
| Accumulated deficit | (1,111,272 | ) | (976,570 | ) | ||||
| Total stockholders’ equity | 134,798 | 211,605 | ||||||
| Total liabilities and stockholders’ equity | $ | 574,144 | $ | 691,236 | ||||
| CARDLYTICS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Amounts in thousands except per share amounts) | ||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Revenue | $ | 89,167 | $ | 82,503 | $ | 309,204 | $ | 298,542 | ||||||||
| Costs and expenses: | ||||||||||||||||
| Partner Share and other third-party costs | 41,880 | 42,511 | 150,578 | 155,507 | ||||||||||||
| Delivery costs | 7,797 | 6,583 | 28,248 | 30,403 | ||||||||||||
| Sales and marketing expense | 14,111 | 16,825 | 57,425 | 74,745 | ||||||||||||
| Research and development expense | 12,512 | 14,801 | 51,352 | 54,435 | ||||||||||||
| General and administration expense | 13,904 | 20,065 | 58,810 | 81,446 | ||||||||||||
| Acquisition, integration and divestiture costs (benefits) | 1,833 | 1,395 | (6,313 | ) | (2,874 | ) | ||||||||||
| Change in fair value of contingent consideration | 16,291 | (14,030 | ) | 1,246 | (128,174 | ) | ||||||||||
| Impairment of goodwill and intangible assets | 70,518 | 370,139 | 70,518 | 453,288 | ||||||||||||
| Loss on divestiture | 6,550 | — | 6,550 | — | ||||||||||||
| Depreciation and amortization expense | 6,695 | 6,849 | 26,460 | 37,544 | ||||||||||||
| Total costs and expenses | 192,091 | 465,138 | 444,874 | 756,320 | ||||||||||||
| Operating loss | (102,924 | ) | (382,635 | ) | (135,670 | ) | (457,778 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest expense, net | (839 | ) | (150 | ) | (2,336 | ) | (2,556 | ) | ||||||||
| Foreign currency gain (loss) | 2,925 | 4,506 | 3,304 | (6,376 | ) | |||||||||||
| Total other income (expense) | 2,086 | 4,356 | 968 | (8,932 | ) | |||||||||||
| Loss before income taxes | (100,838 | ) | (378,279 | ) | (134,702 | ) | (466,710 | ) | ||||||||
| Income tax benefit | — | — | — | 1,446 | ||||||||||||
| Net Loss | (100,838 | ) | (378,279 | ) | (134,702 | ) | (465,264 | ) | ||||||||
| Net Loss attributable to common stockholders | $ | (100,838 | ) | $ | (378,279 | ) | $ | (134,702 | ) | $ | (465,264 | ) | ||||
| Net Loss per share attributable to common stockholders, basic and diluted | $ | (2.56 | ) | $ | (11.32 | ) | $ | (3.69 | ) | $ | (13.92 | ) | ||||
| Weighted-average common shares outstanding, basic and diluted | 39,454 | 33,419 | 36,488 | 33,419 | ||||||||||||
| CARDLYTICS, INC. STOCK-BASED COMPENSATION EXPENSE (Amounts in thousands) | ||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Delivery costs | $ | 627 | $ | 266 | $ | 2,427 | $ | 2,682 | ||||||||
| Sales and marketing expense | 3,137 | 3,170 | 12,624 | 11,935 | ||||||||||||
| Research and development expense | 4,144 | 3,843 | 16,392 | 13,262 | ||||||||||||
| General and administration expense | 3,116 | 5,213 | 9,537 | 16,807 | ||||||||||||
| Total stock-based compensation expense | $ | 11,024 | $ | 12,492 | $ | 40,980 | $ | 44,686 | ||||||||
| CARDLYTICS, INC. CONSOLIDATED STATEMENTS OF CASHFLOWS (Amounts in thousands) | ||||||||
| Year Ended December 31, | ||||||||
| 2023 | 2022 | |||||||
| Operating activities | ||||||||
| Net Loss | $ | (134,702 | ) | $ | (465,264 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Credit loss expense | 1,704 | 2,399 | ||||||
| Depreciation and amortization | 26,460 | 37,544 | ||||||
| Amortization of financing costs charged to interest expense | 1,648 | 1,595 | ||||||
| Amortization of right-of-use assets | 3,055 | 6,196 | ||||||
| Impairment of goodwill and intangible assets | 70,518 | 453,288 | ||||||
| Loss on divestiture | 6,550 | — | ||||||
| Stock-based compensation expense | 40,980 | 44,686 | ||||||
| Change in fair value of contingent consideration | 1,246 | (128,174 | ) | |||||
| Other non-cash (income) expense, net | (4,170 | ) | 6,589 | |||||
| Income tax benefit | — | (1,446 | ) | |||||
| Change in operating assets and liabilities: | ||||||||
| Accounts receivable and contract assets, net | (7,725 | ) | (4,546 | ) | ||||
| Prepaid expenses and other assets | 2,492 | 535 | ||||||
| Accounts payable | 239 | (893 | ) | |||||
| Other accrued expenses | (7,492 | ) | (9,516 | ) | ||||
| Partner Share liability | 405 | 1,721 | ||||||
| Customer Incentive liability | (1,393 | ) | 1,382 | |||||
| Net cash used in operating activities | (185 | ) | (53,904 | ) | ||||
| Investing activities | ||||||||
| Acquisition of property and equipment | (667 | ) | (1,171 | ) | ||||
| Acquisition of patents | — | (175 | ) | |||||
| Capitalized software development costs | (11,725 | ) | (12,140 | ) | ||||
| Business acquisitions, net of cash acquired | — | (2,274 | ) | |||||
| Proceeds from divestitures, net of cash divested | 2,330 | — | ||||||
| Net cash used in investing activities | (10,062 | ) | (15,760 | ) | ||||
| Financing activities | ||||||||
| Proceeds from issuance of debt | 30,000 | — | ||||||
| Principal payments of debt | (31 | ) | (35 | ) | ||||
| Proceeds from issuance of common stock | 55 | 379 | ||||||
| Settlement of contingent consideration | (50,050 | ) | — | |||||
| Deferred equity issuance costs | — | (157 | ) | |||||
| Repurchase of common stock | — | (40,000 | ) | |||||
| Debt issuance costs | — | (174 | ) | |||||
| Net cash used in financing activities | (20,026 | ) | (39,987 | ) | ||||
| Effect of exchange rates on cash, cash equivalents and restricted cash | 118 | (1,926 | ) | |||||
| Net decrease in cash, cash equivalents and restricted cash | (30,155 | ) | (111,577 | ) | ||||
| Cash, cash equivalents, and restricted cash — Beginning of period | 121,985 | 233,562 | ||||||
| Cash, cash equivalents, and restricted cash — End of period | $ | 91,830 | $ | 121,985 | ||||
| CARDLYTICS, INC. RECONCILIATION OF GAAP REVENUE TO BILLINGS (Amounts in thousands) | ||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Consolidated | ||||||||||||||||
| Revenue | $ | 89,167 | $ | 82,503 | $ | 309,204 | $ | 298,542 | ||||||||
| Plus: | ||||||||||||||||
| Consumer Incentives | 42,780 | 43,613 | 144,222 | 143,935 | ||||||||||||
| Billings | $ | 131,947 | $ | 126,116 | $ | 453,426 | $ | 442,477 | ||||||||
| Cardlytics platform | ||||||||||||||||
| Revenue | $ | 82,604 | $ | 76,647 | $ | 285,425 | $ | 277,185 | ||||||||
| Plus: | ||||||||||||||||
| Consumer Incentives | 42,780 | 43,613 | 144,222 | 143,935 | ||||||||||||
| Billings | $ | 125,384 | $ | 120,260 | $ | 429,647 | $ | 421,120 | ||||||||
| Bridg platform | ||||||||||||||||
| Revenue | $ | 6,563 | $ | 5,856 | $ | 23,779 | $ | 21,357 | ||||||||
| Plus: | ||||||||||||||||
| Consumer Incentives | — | — | — | — | ||||||||||||
| Billings | $ | 6,563 | $ | 5,856 | $ | 23,779 | $ | 21,357 | ||||||||
| CARDLYTICS, INC. RECONCILIATION OF GAAP GROSS PROFIT TO ADJUSTED CONTRIBUTION (Amounts in thousands) | ||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Consolidated | ||||||||||||||||
| Revenue | $ | 89,167 | $ | 82,503 | $ | 309,204 | $ | 298,542 | ||||||||
| Minus: | ||||||||||||||||
| Partner Share and other third-party costs | 41,880 | 42,511 | 150,578 | 155,507 | ||||||||||||
| Delivery costs(1) | 7,797 | 6,583 | 28,248 | 30,403 | ||||||||||||
| Gross Profit | 39,490 | 33,409 | 130,378 | 112,632 | ||||||||||||
| Plus: | ||||||||||||||||
| Delivery costs(1) | 7,797 | 6,583 | 28,248 | 30,403 | ||||||||||||
| Adjusted Contribution | $ | 47,287 | $ | 39,992 | $ | 158,626 | $ | 143,035 | ||||||||
| Cardlytics platform | ||||||||||||||||
| Revenue | $ | 82,604 | $ | 76,647 | $ | 285,425 | $ | 277,185 | ||||||||
| Minus: | ||||||||||||||||
| Partner Share and other third-party costs | 41,635 | 42,375 | 149,907 | 154,204 | ||||||||||||
| Delivery costs(1) | 6,027 | 5,271 | 21,447 | 24,112 | ||||||||||||
| Gross Profit | 34,942 | 29,001 | 114,071 | 98,869 | ||||||||||||
| Plus: | ||||||||||||||||
| Delivery costs(1) | 6,027 | 5,271 | 21,447 | 24,112 | ||||||||||||
| Adjusted Contribution | $ | 40,969 | $ | 34,272 | $ | 135,518 | $ | 122,981 | ||||||||
| Bridg platform | ||||||||||||||||
| Revenue | $ | 6,563 | $ | 5,856 | $ | 23,779 | $ | 21,357 | ||||||||
| Minus: | ||||||||||||||||
| Partner Share and other third-party costs | 245 | 136 | 671 | 1,303 | ||||||||||||
| Delivery costs(1) | 1,770 | 1,312 | 6,801 | 6,291 | ||||||||||||
| Gross Profit | 4,548 | 4,408 | 16,307 | 13,763 | ||||||||||||
| Plus: | ||||||||||||||||
| Delivery costs(1) | 1,770 | 1,312 | 6,801 | 6,291 | ||||||||||||
| Adjusted Contribution | $ | 6,318 | $ | 5,720 | $ | 23,108 | $ | 20,054 | ||||||||
| (1) Stock-based compensation expense recognized in consolidated delivery costs totaled | ||||||||||||||||
| CARDLYTICS, INC. RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA (Amounts in thousands) | ||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Net Loss | $ | (100,838 | ) | $ | (378,279 | ) | $ | (134,702 | ) | $ | (465,264 | ) | ||||
| Plus: | ||||||||||||||||
| Interest expense, net | 839 | 150 | 2,336 | 2,556 | ||||||||||||
| Depreciation and amortization | 6,695 | 6,849 | 26,460 | 37,544 | ||||||||||||
| Stock-based compensation expense | 11,024 | 12,492 | 40,980 | 44,686 | ||||||||||||
| Acquisition, integration and divestiture costs (benefits) | 1,833 | 1,395 | (6,313 | ) | (2,874 | ) | ||||||||||
| Change in fair value of contingent consideration | 16,291 | (14,030 | ) | 1,246 | (128,174 | ) | ||||||||||
| Foreign currency (gain) loss | (2,925 | ) | (4,506 | ) | (3,304 | ) | 6,376 | |||||||||
| Impairment of goodwill and intangible assets | 70,518 | 370,139 | 70,518 | 453,288 | ||||||||||||
| Loss on divestiture | 6,550 | — | 6,550 | — | ||||||||||||
| Restructuring and reduction of force | — | (347 | ) | — | 8,139 | |||||||||||
| Income tax benefit | — | — | — | (1,446 | ) | |||||||||||
| Adjusted EBITDA | $ | 9,987 | $ | (6,137 | ) | $ | 3,771 | $ | (45,169 | ) | ||||||
| CARDLYTICS, INC. RECONCILIATION OF ADJUSTED CONTRIBUTION TO ADJUSTED EBITDA (Amounts in thousands) | ||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Consolidated | ||||||||||||||||
| Adjusted Contribution | $ | 47,287 | $ | 39,992 | $ | 158,626 | $ | 143,034 | ||||||||
| Minus: | ||||||||||||||||
| Delivery costs | 7,797 | 6,583 | 28,248 | 30,402 | ||||||||||||
| Sales and marketing expense | 14,111 | 16,825 | 57,425 | 74,745 | ||||||||||||
| Research and development expense | 12,512 | 14,801 | 51,352 | 54,435 | ||||||||||||
| General and administration expense | 13,904 | 20,065 | 58,810 | 81,446 | ||||||||||||
| Stock-based compensation expense | (11,024 | ) | (12,492 | ) | (40,980 | ) | (44,686 | ) | ||||||||
| Restructuring and reduction of force | — | 347 | — | (8,139 | ) | |||||||||||
| Adjusted EBITDA | $ | 9,987 | $ | (6,137 | ) | $ | 3,771 | $ | (45,169 | ) | ||||||
| Cardlytics platform | ||||||||||||||||
| Adjusted Contribution | $ | 40,969 | $ | 34,272 | $ | 135,518 | $ | 122,981 | ||||||||
| Minus: | ||||||||||||||||
| Delivery costs | 6,027 | 5,271 | 21,447 | 24,112 | ||||||||||||
| Sales and marketing expense | 12,249 | 14,484 | 48,671 | 67,830 | ||||||||||||
| Research and development expense | 10,975 | 13,002 | 45,746 | 47,579 | ||||||||||||
| General and administration expense | 13,222 | 19,070 | 56,542 | 79,069 | ||||||||||||
| Stock-based compensation expense | (9,947 | ) | (12,309 | ) | (37,782 | ) | (43,490 | ) | ||||||||
| Restructuring and reduction of force | — | 347 | — | (8,139 | ) | |||||||||||
| Adjusted EBITDA | $ | 8,443 | $ | (5,593 | ) | $ | 894 | $ | (43,980 | ) | ||||||
| Bridg platform | ||||||||||||||||
| Adjusted Contribution | $ | 6,318 | $ | 5,720 | $ | 23,108 | $ | 20,053 | ||||||||
| Minus: | ||||||||||||||||
| Delivery costs | 1,770 | 1,312 | 6,801 | 6,290 | ||||||||||||
| Sales and marketing expense | 1,862 | 2,341 | 8,754 | 6,915 | ||||||||||||
| Research and development expense | 1,537 | 1,799 | 5,606 | 6,856 | ||||||||||||
| General and administration expense | 682 | 995 | 2,268 | 2,377 | ||||||||||||
| Stock-based compensation expense | (1,077 | ) | (183 | ) | (3,198 | ) | (1,196 | ) | ||||||||
| Restructuring and reduction of force | — | — | — | — | ||||||||||||
| Adjusted EBITDA | $ | 1,544 | $ | (544 | ) | $ | 2,877 | $ | (1,189 | ) | ||||||
| CARDLYTICS, INC. RECONCILIATION OF GAAP NET LOSS TO ADJUSTED NET INCOME (LOSS) AND ADJUSTED NET INCOME (LOSS) PER SHARE (Amounts in thousands except per share amounts) | ||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Net Loss | $ | (100,838 | ) | $ | (378,279 | ) | $ | (134,702 | ) | $ | (465,264 | ) | ||||
| Plus: | ||||||||||||||||
| Stock-based compensation expense | 11,024 | 12,492 | 40,980 | 44,686 | ||||||||||||
| Foreign currency (gain) loss | (2,925 | ) | (4,506 | ) | (3,304 | ) | 6,376 | |||||||||
| Acquisition, integration and divestiture costs (benefits) | 1,833 | 1,395 | (6,313 | ) | (2,874 | ) | ||||||||||
| Amortization of acquired intangibles | 3,258 | 3,459 | 13,589 | 25,019 | ||||||||||||
| Change in fair value of contingent consideration | 16,291 | (14,030 | ) | 1,246 | (128,174 | ) | ||||||||||
| Impairment of goodwill and intangible assets | 70,518 | 370,139 | 70,518 | 453,288 | ||||||||||||
| Loss on divestiture | 6,550 | — | 6,550 | — | ||||||||||||
| Restructuring and reduction of force | — | (347 | ) | — | 8,139 | |||||||||||
| Income tax benefit | — | — | — | (1,446 | ) | |||||||||||
| Adjusted Net Income (Loss) | $ | 5,711 | $ | (9,677 | ) | $ | (11,436 | ) | $ | (60,250 | ) | |||||
| Weighted-average number of shares of common stock used in computing Adjusted Net Income (Loss) per share: | ||||||||||||||||
| Weighted-average common shares outstanding, diluted | 39,454 | 33,419 | 36,488 | 33,419 | ||||||||||||
| Adjusted Net Income (Loss) per share attributable to common stockholders, diluted | $ | 0.14 | $ | (0.29 | ) | $ | (0.31 | ) | $ | (1.80 | ) | |||||
| CARDLYTICS, INC. RECONCILIATION OF NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES TO FREE CASH FLOW (Amounts in thousands) | ||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Net cash provided by (used in) operating activities | $ | 2,934 | $ | (13,101 | ) | $ | (185 | ) | $ | (53,904 | ) | |||||
| Plus: | ||||||||||||||||
| Acquisition of property and equipment | (274 | ) | (82 | ) | (667 | ) | (1,171 | ) | ||||||||
| Acquisition of patents | — | (101 | ) | — | (175 | ) | ||||||||||
| Capitalized software development costs | (3,423 | ) | (2,970 | ) | (11,725 | ) | (12,140 | ) | ||||||||
| Free Cash Flow | $ | (763 | ) | $ | (16,254 | ) | $ | (12,577 | ) | $ | (67,390 | ) | ||||
| CARDLYTICS, INC. RECONCILIATION OF FORECASTED GAAP REVENUE TO BILLINGS (Amounts in millions) | |
| Q1 2024 Guidance | |
| Revenue | |
| Plus: | |
| Consumer Incentives | |
| Billings | |
Contacts:
Public Relations:
pr@cardlytics.com
Investor Relations:
ir@cardlytics.com
FAQ
What were Cardlytics' Q4 2023 Total Revenue and Billings?
What was Cardlytics' Q4 2023 Adjusted EBITDA?
What was Cardlytics' Q4 2023 Net Loss attributable to common stockholders?
What were Cardlytics' full year 2023 Total Revenue and Billings?
What was Cardlytics' full year 2023 Adjusted EBITDA?
What was Cardlytics' full year 2023 Net Loss attributable to common stockholders?
What were Cardlytics' Q4 2023 MAUs and ARPU?
What were Cardlytics' full year 2023 MAUs and ARPU?
What are Cardlytics' Q1 2024 financial expectations for Billings and Revenue?
When is Cardlytics' earnings teleconference scheduled?
